Compare Novavax Inc (NVAX) vs ProShares Ultra QQQ ETF (QLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs ProShares Ultra QQQ ETF — how do they compare? Novavax Inc trades at $8.14 (market cap $1.31B), while ProShares Ultra QQQ ETF trades at $94.33. The key difference: ProShares Ultra QQQ ETF is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| NVAX | QLD | |
|---|---|---|
Market Cap | $1.31B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $11.19 | $100.53 |
52-Week Low | $6.22 | $57.16 |
Enterprise Value | $890.95M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $8.14, up 2.39% today, with a bearish technical signal despite recent earnings beats. The company reported a net loss of $53 million in Q2 2026 but raised its full-year revenue outlook, driven by licensing milestones from its Sanofi partnership. Valuation ratios like P/E of 3.14 and EV/EBITDA of 1.72 appear low, yet negative profitability margins and cash flow challenges persist.
The outlook is mixed: analyst consensus is 74% buy with potential from partnerships, but risks include sustained losses, high debt, and competitive vaccine market pressure. Investors should weigh the low valuation against fundamental weaknesses and monitor execution on cost reductions and pipeline progress for upside catalysts.
QLD, a 2x leveraged ETF tracking the Nasdaq-100, trades at $92.32, up 1.41% today, with a bullish technical signal from moving averages. The ETF has delivered over 10,000% total return since inception, per Seeking Alpha on 2026-06-21, but lacks traditional financial ratios due to its structure. Recent news highlights institutional buying and tactical opportunities in tech.
Outlook is cautiously optimistic given bullish momentum and AI-driven tech exposure, but risks include daily leverage decay and market volatility. Investors face amplified gains or losses, with a maximum drawdown of 63.80% historically, as noted by The Motley Fool on 2026-05-13.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →
